DK3536324T3 - 4-oxo-3,4-dihydro-1,2,3-benzotriaziner som modulatorer af gpr139 - Google Patents

4-oxo-3,4-dihydro-1,2,3-benzotriaziner som modulatorer af gpr139 Download PDF

Info

Publication number: DK3536324T3
Authority: DK; Denmark
Prior art keywords: gpr139; benzotriazines; modulators; dihydro; oxo
Prior art date: 2014-11-20

Application number

DK19152036.0T

Other languages

English (en)

Inventor

Stephan Hitchcock

Betty Lam

Holger Monenschein

Holly Reichard

Original Assignee

Takeda Pharmaceuticals Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-11-20

Filing date

2015-11-19

Publication date

2021-10-25

2015-11-19 Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co

2021-10-25 Application granted granted Critical

2021-10-25 Publication of DK3536324T3 publication Critical patent/DK3536324T3/da

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/08—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 condensed with carbocyclic rings or ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/08—Radicals containing only hydrogen and carbon atoms

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Psychiatry (AREA)
Epidemiology (AREA)
Pain & Pain Management (AREA)
Physical Education & Sports Medicine (AREA)
Hospice & Palliative Care (AREA)
Hematology (AREA)
Orthopedic Medicine & Surgery (AREA)
Child & Adolescent Psychology (AREA)
Diabetes (AREA)
Anesthesiology (AREA)
Obesity (AREA)
Addiction (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

DK19152036.0T 2014-11-20 2015-11-19 4-oxo-3,4-dihydro-1,2,3-benzotriaziner som modulatorer af gpr139 DK3536324T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201462082539P	2014-11-20	2014-11-20
US201562184729P	2015-06-25	2015-06-25
EP15816275.0A EP3221298B1 (en)	2014-11-20	2015-11-19	4-oxo-3,4-dihydro-1,2,3-benzotriazine derivatives as modulators of gpr139

Publications (1)

Publication Number	Publication Date
DK3536324T3 true DK3536324T3 (da)	2021-10-25

Family

ID=55022667

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK19152036.0T DK3536324T3 (da)	2014-11-20	2015-11-19	4-oxo-3,4-dihydro-1,2,3-benzotriaziner som modulatorer af gpr139
DK15816275.0T DK3221298T3 (da)	2014-11-20	2015-11-19	4-oxo-3,4-dihydro-1,2,3-benzotriazinderivater som modulatorer af gpr139

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DK15816275.0T DK3221298T3 (da)	2014-11-20	2015-11-19	4-oxo-3,4-dihydro-1,2,3-benzotriazinderivater som modulatorer af gpr139

Country Status (40)

Country	Link
US (5)	US9556130B2 (da)
EP (2)	EP3221298B1 (da)
JP (2)	JP6637501B2 (da)
KR (1)	KR102582021B1 (da)
CN (2)	CN107108531B (da)
AU (1)	AU2015349866B2 (da)
CA (1)	CA2968242C (da)
CL (1)	CL2017001292A1 (da)
CO (1)	CO2017005959A2 (da)
CR (1)	CR20170275A (da)
CY (2)	CY1122613T1 (da)
DK (2)	DK3536324T3 (da)
DO (1)	DOP2017000120A (da)
EA (1)	EA033728B1 (da)
EC (1)	ECSP17038999A (da)
ES (2)	ES2734735T3 (da)
GE (1)	GEP20196961B (da)
HR (2)	HRP20191003T1 (da)
HU (2)	HUE044145T2 (da)
IL (1)	IL252311B (da)
JO (1)	JO3719B1 (da)
LT (2)	LT3536324T (da)
MA (1)	MA40993B1 (da)
MD (1)	MD3221298T2 (da)
MX (1)	MX378158B (da)
MY (1)	MY187423A (da)
NZ (1)	NZ732208A (da)
PE (1)	PE20170899A1 (da)
PH (1)	PH12017500920A1 (da)
PL (2)	PL3221298T3 (da)
PT (2)	PT3221298T (da)
RS (2)	RS62563B1 (da)
SG (1)	SG11201704002UA (da)
SI (2)	SI3221298T1 (da)
SM (2)	SMT201900355T1 (da)
TN (1)	TN2017000196A1 (da)
TW (1)	TWI684590B (da)
UA (1)	UA120375C2 (da)
UY (1)	UY36406A (da)
WO (1)	WO2016081736A1 (da)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JO3719B1 (ar) *	2014-11-20	2021-01-31	Takeda Pharmaceuticals Co	4- أوكسو-4،3- داي هيدرو-3،2،1- بنزوترايازينات كمواد ضابطة لأجل gpr139
US12042496B2 (en)	2018-10-16	2024-07-23	The University Of Florida Research Foundation, Incorporated	Methods related to opioid therapeutics
WO2020097609A1 (en) *	2018-11-09	2020-05-14	Blackthorn Therapeutics, Inc.	Gpr139 receptor modulators
CR20220160A (es) *	2019-09-16	2022-06-16	Takeda Pharmaceuticals Co	Derivados de piridazin-3(2h)-ona fusionados con azol
WO2021127459A1 (en) *	2019-12-20	2021-06-24	Blackthorn Therapeutics, Inc.	Gpr139 receptor modulators
JP7697974B2 (ja) *	2020-05-08	2025-06-24	武田薬品工業株式会社	Ｇｐｒ１３９アゴニストの置換ベンゾトリアジノン代謝物
JP2023541485A (ja) *	2020-09-21	2023-10-02	武田薬品工業株式会社	統合失調症のための処置
US11760788B2 (en)	2021-03-02	2023-09-19	Pathways Neuro Pharma, Inc.	Neuroreceptor compositions and methods of use
CN116693545A (zh) *	2022-03-01	2023-09-05	上海科技大学	噻吩并含氮杂环类化合物、含其的药物组合物、其制备方法及其应用
WO2023165263A1 (zh) *	2022-03-01	2023-09-07	上海科技大学	吡咯并三嗪酮类化合物、含其的药物组合物、其制备方法及其应用
CN117986183A (zh) *	2022-10-28	2024-05-07	浙江友宁生物医药科技有限公司	一种gpr139受体激动剂、其制备方法及其应用
WO2024102802A1 (en) *	2022-11-11	2024-05-16	Takeda Pharmaceutical Company Limited	Zelatriazin for the treatment of depression
WO2025119351A1 (zh) *	2023-12-08	2025-06-12	深圳湾实验室	Gpr139激动剂
WO2025162441A1 (zh) *	2024-02-02	2025-08-07	上海科技大学	稠杂环类化合物与其制备方法、药物组合物及应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3794726A (en) *	1972-08-21	1974-02-26	Uniroyal Inc	Inhibiting aggressive behavior with 1,2,3-benzotriazin-(3h)-one
WO1987004928A1 (fr)	1986-02-24	1987-08-27	Mitsui Petrochemical Industries, Ltd.	Agents therapeutiques de la neuropathie
ATE108791T1 (de)	1987-11-04	1994-08-15	Beecham Group Plc	Neue 4-oxobenzotriazine und 4-oxochinazoline.
PE20050630A1 (es)	2003-06-09	2005-09-22	Boehringer Ingelheim Int	Compuestos heterociclicos como inhibidores del papiloma virus
CA2533824A1 (en)	2003-07-31	2005-02-10	Irm, Llc	Bicyclic compounds and compositions as pdf inhibitors
FR2875805B1 (fr)	2004-09-27	2006-12-29	Genfit S A	Composes derives de n-(benzyl) phenylacetamide substitues, preparation et utilisations
UY30048A1 (es)	2005-12-23	2007-07-31	Astrazeneca Ab	Derivados sustituidos de la n,2-(1h-benzimidazol-1-il) acetamida, composiciones farmacéuticas conteniéndolos, procesos de preparación y aplicaciones
TWI433839B (zh)	2006-08-11	2014-04-11	Neomed Inst	新穎的苯并咪唑衍生物290
MX2009010218A (es) *	2007-03-23	2009-10-19	Hoffmann La Roche	Derivados de aza-piridopirimidinona.
CA2709784A1 (en) *	2007-12-21	2009-07-09	University Of Rochester	Method for altering the lifespan of eukaryotic organisms
WO2011138265A2 (en)	2010-05-03	2011-11-10	Evotec Ag	Indole and indazole derivatives as orexin receptor antagonists
JP2016515138A (ja) *	2013-03-14	2016-05-26	ヤンセンファーマシューティカエヌ．ベー．	Ｇｐｒ１３９の生理的リガンド
JO3719B1 (ar) *	2014-11-20	2021-01-31	Takeda Pharmaceuticals Co	4- أوكسو-4،3- داي هيدرو-3،2،1- بنزوترايازينات كمواد ضابطة لأجل gpr139

2015
- 2015-11-18 JO JOP/2015/0282A patent/JO3719B1/ar active
- 2015-11-19 ES ES15816275T patent/ES2734735T3/es active Active
- 2015-11-19 RS RS20211398A patent/RS62563B1/sr unknown
- 2015-11-19 SM SM20190355T patent/SMT201900355T1/it unknown
- 2015-11-19 TN TN2017000196A patent/TN2017000196A1/en unknown
- 2015-11-19 GE GEAP201514515A patent/GEP20196961B/en unknown
- 2015-11-19 SG SG11201704002UA patent/SG11201704002UA/en unknown
- 2015-11-19 EA EA201791096A patent/EA033728B1/ru unknown
- 2015-11-19 SI SI201530772T patent/SI3221298T1/sl unknown
- 2015-11-19 SM SM20220142T patent/SMT202200142T1/it unknown
- 2015-11-19 KR KR1020177016973A patent/KR102582021B1/ko active Active
- 2015-11-19 RS RS20190776A patent/RS59078B1/sr unknown
- 2015-11-19 ES ES19152036T patent/ES2897545T3/es active Active
- 2015-11-19 PL PL15816275T patent/PL3221298T3/pl unknown
- 2015-11-19 LT LTEP19152036.0T patent/LT3536324T/lt unknown
- 2015-11-19 NZ NZ732208A patent/NZ732208A/en unknown
- 2015-11-19 PE PE2017000866A patent/PE20170899A1/es unknown
- 2015-11-19 CN CN201580071393.8A patent/CN107108531B/zh active Active
- 2015-11-19 MY MYPI2017701778A patent/MY187423A/en unknown
- 2015-11-19 CR CR20170275A patent/CR20170275A/es unknown
- 2015-11-19 EP EP15816275.0A patent/EP3221298B1/en active Active
- 2015-11-19 PL PL19152036T patent/PL3536324T3/pl unknown
- 2015-11-19 LT LTEP15816275.0T patent/LT3221298T/lt unknown
- 2015-11-19 CN CN202010988947.3A patent/CN112062730B/zh active Active
- 2015-11-19 MX MX2017006448A patent/MX378158B/es unknown
- 2015-11-19 PT PT15816275T patent/PT3221298T/pt unknown
- 2015-11-19 CA CA2968242A patent/CA2968242C/en active Active
- 2015-11-19 DK DK19152036.0T patent/DK3536324T3/da active
- 2015-11-19 PT PT191520360T patent/PT3536324T/pt unknown
- 2015-11-19 MA MA40993A patent/MA40993B1/fr unknown
- 2015-11-19 HU HUE15816275A patent/HUE044145T2/hu unknown
- 2015-11-19 AU AU2015349866A patent/AU2015349866B2/en active Active
- 2015-11-19 MD MDE20170117 patent/MD3221298T2/ro unknown
- 2015-11-19 US US14/946,194 patent/US9556130B2/en active Active
- 2015-11-19 SI SI201531729T patent/SI3536324T1/sl unknown
- 2015-11-19 WO PCT/US2015/061607 patent/WO2016081736A1/en not_active Ceased
- 2015-11-19 HR HRP20191003TT patent/HRP20191003T1/hr unknown
- 2015-11-19 UY UY0001036406A patent/UY36406A/es not_active Application Discontinuation
- 2015-11-19 EP EP19152036.0A patent/EP3536324B1/en active Active
- 2015-11-19 JP JP2017526844A patent/JP6637501B2/ja active Active
- 2015-11-19 HR HRP20212009TT patent/HRP20212009T1/hr unknown
- 2015-11-19 HU HUE19152036A patent/HUE057451T2/hu unknown
- 2015-11-19 DK DK15816275.0T patent/DK3221298T3/da active
- 2015-11-19 TW TW104138295A patent/TWI684590B/zh active
- 2015-11-19 UA UAA201705041A patent/UA120375C2/uk unknown
2016
- 2016-12-16 US US15/382,490 patent/US9770450B2/en active Active
2017
- 2017-05-12 DO DO2017000120A patent/DOP2017000120A/es unknown
- 2017-05-16 IL IL252311A patent/IL252311B/en active IP Right Grant
- 2017-05-18 PH PH12017500920A patent/PH12017500920A1/en unknown
- 2017-05-19 CL CL2017001292A patent/CL2017001292A1/es unknown
- 2017-06-16 CO CONC2017/0005959A patent/CO2017005959A2/es unknown
- 2017-06-20 EC ECIEPI201738999A patent/ECSP17038999A/es unknown
- 2017-08-22 US US15/683,589 patent/US10159677B2/en active Active
2018
- 2018-11-02 US US16/179,709 patent/US10561662B2/en active Active
2019
- 2019-06-20 CY CY20191100646T patent/CY1122613T1/el unknown
- 2019-12-20 JP JP2019229837A patent/JP6918088B2/ja active Active
2020
- 2020-01-02 US US16/732,536 patent/US11173161B2/en active Active
2021
- 2021-12-17 CY CY20211101111T patent/CY1124929T1/el unknown

Also Published As

Publication number	Publication date
CA2968242C (en)	2022-11-08
JO3719B1 (ar)	2021-01-31
PH12017500920B1 (en)	2017-11-20
HRP20191003T1 (hr)	2019-08-23
JP6918088B2 (ja)	2021-08-11
TW201625566A (zh)	2016-07-16
JP2020063285A (ja)	2020-04-23
ES2734735T3 (es)	2019-12-11
CN112062730B (zh)	2023-09-29
BR112017010311A2 (pt)	2017-12-26
TN2017000196A1 (en)	2018-10-19
EP3221298A1 (en)	2017-09-27
US10561662B2 (en)	2020-02-18
LT3536324T (lt)	2021-12-10
AU2015349866A1 (en)	2017-06-15
PT3221298T (pt)	2019-06-28
SI3221298T1 (sl)	2019-10-30
SG11201704002UA (en)	2017-06-29
CN112062730A (zh)	2020-12-11
US20190070187A1 (en)	2019-03-07
CA2968242A1 (en)	2016-05-26
US11173161B2 (en)	2021-11-16
KR20170084324A (ko)	2017-07-19
US20170095480A1 (en)	2017-04-06
TWI684590B (zh)	2020-02-11
HUE057451T2 (hu)	2022-05-28
JP2017535559A (ja)	2017-11-30
CR20170275A (es)	2017-10-30
PH12017500920A1 (en)	2017-11-20
PE20170899A1 (es)	2017-07-12
PL3536324T3 (pl)	2022-02-07
HUE044145T2 (hu)	2019-09-30
CO2017005959A2 (es)	2017-10-20
RS62563B1 (sr)	2021-12-31
ECSP17038999A (es)	2017-10-31
MX378158B (es)	2025-03-10
DK3221298T3 (da)	2019-06-24
GEP20196961B (en)	2019-03-25
PT3536324T (pt)	2021-11-10
IL252311B (en)	2020-07-30
EA033728B1 (ru)	2019-11-20
SMT202200142T1 (it)	2022-05-12
NZ732208A (en)	2023-02-24
US20160145218A1 (en)	2016-05-26
CN107108531A (zh)	2017-08-29
US20200129518A1 (en)	2020-04-30
AU2015349866B2 (en)	2020-12-03
EP3221298B1 (en)	2019-04-03
CN107108531B (zh)	2020-10-20
ES2897545T3 (es)	2022-03-01
UA120375C2 (uk)	2019-11-25
EP3536324B1 (en)	2021-10-06
JP6637501B2 (ja)	2020-01-29
CY1124929T1 (el)	2023-01-05
KR102582021B1 (ko)	2023-09-22
US9556130B2 (en)	2017-01-31
EA201791096A1 (ru)	2017-11-30
US9770450B2 (en)	2017-09-26
SI3536324T1 (sl)	2021-12-31
PL3221298T3 (pl)	2019-10-31
CL2017001292A1 (es)	2018-02-16
IL252311A0 (en)	2017-07-31
MA40993A (fr)	2017-09-27
MA40993B1 (fr)	2019-07-31
HRP20212009T1 (hr)	2022-04-01
MX2017006448A (es)	2017-09-12
DOP2017000120A (es)	2017-06-15
MY187423A (en)	2021-09-22
CY1122613T1 (el)	2021-05-05
MD3221298T2 (ro)	2019-10-31
LT3221298T (lt)	2019-08-12
WO2016081736A1 (en)	2016-05-26
RS59078B1 (sr)	2019-09-30
US10159677B2 (en)	2018-12-25
EP3536324A1 (en)	2019-09-11
UY36406A (es)	2016-06-30
US20170348319A1 (en)	2017-12-07
SMT201900355T1 (it)	2019-07-11

Publication	Publication Date	Title
DK3536324T3 (da)	2021-10-25	4-oxo-3,4-dihydro-1,2,3-benzotriaziner som modulatorer af gpr139
DK3521282T3 (da)	2021-09-27	Quinazolinderivater anvendt til behandling af hiv
DK3096741T3 (da)	2020-09-28	Fremgangsmåde til fremstillingen af hybridosomer
DK3137169T3 (da)	2022-02-14	Hæmmere af lysin-specifik demethylase-1
BR112016030368A2 (pt)	2018-07-17	composição oftálmica
DK3572416T3 (da)	2022-12-12	Diaryl-makrocykler som modulatorer af proteinkinaser
DK3192902T3 (da)	2019-07-15	Fremgangsmåde til fremstilling af graphenholdige viscosefibre
DK3357919T3 (da)	2020-02-17	Aromatiske heterocykliske forbindelser som antiinflammatoriske forbindelser
DK3294713T3 (da)	2021-05-10	Substituerede tetrahydroquinolinonforbindelser som ror-gamma-modulatorer
DK3131902T3 (da)	2019-09-02	Forbindelser som ROR-gamma-modulatorer
DK3094631T3 (da)	2019-05-06	Pyrimidinyloxybenzenderivater som herbicider
DK3174858T3 (da)	2019-07-15	Fremgangsmåde til fremstilling af pyrazoler
DK3204378T6 (da)	2022-07-18	N-pyridinylacetamidderivater som hæmmere af wnt-signaleringsbanen
DK3331863T3 (da)	2020-04-27	Hidtil ukendte forbindelser som ror-gamma-modulatorer
DK3233813T3 (da)	2022-03-07	Fremgangsmåder til fremstilling af oxathiazin-lignende forbindelser
DK3164123T3 (da)	2020-08-03	Hidtil ukendte anvendelser af benzylidenguanidinderivater til behandling af proteopatier
DK3212643T3 (da)	2019-05-13	Trifluormethylalkoholer som modulatorer af ror-gamma-t
DK3280408T3 (da)	2020-02-03	Fremgangsmåde til fremstilling af dicycloplatin
DK3418273T3 (da)	2022-03-21	Derivater af flavagliner
DK3175593T3 (da)	2020-02-24	Signalering af modulationskonfiguration
DK3145916T3 (da)	2020-05-11	Imidazolderivater som formylpeptidreceptormodulatorer
DK3122349T3 (da)	2022-02-14	Sammensætninger til behandling af autodigestion
BR112016018071A2 (pt)	2018-05-08	composição de larvicida.
DK3325489T3 (da)	2020-02-17	Asymmetrisk fremgangsmåde til fremstilling af thien-indolderivater
DK3154942T3 (da)	2019-11-18	Fremstilling af piperidin-4-carbothioamid